Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Big Molecule WatchOn April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.RegulatoryOphthalmologyRead full story pharminent April 15, 2026 Big Molecule Watch On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S. RegulatoryOphthalmologyRead full story Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: Travere wins long-awaited approval for kidney disease drug Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026